Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WP 1220

Next Previous
Drug Profile

WP 1220

Alternative Names: MOL-4239; WP-1220

Latest Information Update: 17 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Dermin; Moleculin; Moleculin Biotech
  • Class Amides; Antineoplastics; Antipsoriatics; Halogenated hydrocarbons; Nitriles; Pyridines; Small molecules
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cutaneous T-cell lymphoma
  • Discontinued Plaque psoriasis

Most Recent Events

  • 31 Mar 2023 Moleculin has patent protection in China, Eurasia, Europe, Japan, Mexico, New Zealand, Singapore, Ukraine and USA
  • 12 Apr 2022 Phase-I/II clinical trials in Cutaneous T-cell lymphoma in Poland (Topical) (WPD Pharmaceuticals pipeline, April 2022)
  • 28 Mar 2022 No recent reports of development identified for phase-I development in Cutaneous-T-cell-lymphoma in Poland (Topical)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top